pyrazines has been researched along with cc214-2 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bisonette, RR; Fultz, KE; Gamez, JC; Harris, R; Hickman, M; Khambatta, G; Lee, BG; Leisten, J; Mortensen, DS; Narla, RK; Parnes, JS; Peng, S; Perrin-Ninkovic, SM; Sankar, S; Sapienza, J; Shevlin, G; Whitefield, B | 1 |
| Akhavan, D; Assuncao, A; Babic, I; Bonetti, B; Cavenee, WK; Chopra, R; Cloughesy, TF; Furnari, FB; Gini, B; Gu, Y; Guo, D; Heath, JR; Hege, K; Ikegami, S; James, CD; Kroemer, G; Lin, K; Masui, K; Matsutani, T; Mischel, PS; Mortensen, DS; Nathanson, D; Raymon, HK; Shackelford, D; Tanaka, K; Villa, GR; Xu, S; Yang, H; Zanca, C; Zhu, S | 1 |
| Almeida, J; Blanco, B; Del Cañizo, C; García-Briñón, J; Herrero-Sánchez, MC; Inogés, S; Rodríguez-Serrano, C; San-Segundo, L; SanMiguel, JF; Santos-Briz, Á | 1 |
| Bonetti, B; Cavenee, WK; Chopra, R; Cloughesy, TF; Ding, X; Gini, B; Gu, Y; Heath, JR; Herrmann, K; Hwang, K; Ikegami, S; James, CD; Johnson, D; Kim, J; Li, X; Masui, K; Matsutani, T; Mischel, PS; Shin, YS; Su, Y; Wei, W; Xue, M; Yang, H; Zhou, J | 1 |
4 other study(ies) available for pyrazines and cc214-2
| Article | Year |
|---|---|
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Half-Life; Humans; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2013 |
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Protein Biosynthesis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
Topics: Animals; Cells, Cultured; Female; Graft vs Host Disease; Humans; Imidazoles; Immune Tolerance; Lymphocyte Activation; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Multiprotein Complexes; Pyrazines; T-Lymphocytes; TOR Serine-Threonine Kinases | 2016 |
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.
Topics: Adaptation, Physiological; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Profiling; Genes, erbB-1; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Models, Biological; Molecular Targeted Therapy; Multiprotein Complexes; Mutation; Neoplasm Proteins; Nitriles; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Pyrazines; Selection, Genetic; Signal Transduction; Single-Cell Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |